Mersana Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
24/02/2025 13:46
* Mersana Therapeutics Inc MRSN.OQ MRSN.O is expected
to show
a fall in quarterly revenue when it reports results on February
26 (estimated) for the period ending December 31 2024
* The Cambridge Massachusetts-based company is expected to
report
a 28.3% decrease in revenue to $7.673 million from $10.7 million
a year ago, according to the mean estimate from 9 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for Mersana Therapeutics Inc
is
for a loss of 16 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Mersana
Therapeutics Inc is $5.00, above its last closing price
of $0.53.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2024 -0.18 -0.18 -0.09 Beat 48.7
Jun. 30 2024 -0.17 -0.17 -0.20 Missed -16.7
Mar. 31 2024 -0.18 -0.18 -0.16 Beat 11.6
Dec. 31 2023 -0.12 -0.16 -0.16 Met 2.6
Sep. -0.35 -0.36 -0.27 Beat 25.4
30 2023
Jun. 30 2023 -0.37 -0.44 -0.47 Missed -6.5
Mar. 31 2023 -0.40 -0.44 -0.52 Missed -19.3
Dec. 31 2022 -0.47 -0.50 -0.44 Beat 12.8
This summary was machine generated February 24 at 13:46 GMT.
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)